DrugCite
Search

RASILEZ HCT

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Rasilez Hct Adverse Events Reported to the FDA Over Time

How are Rasilez Hct adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Rasilez Hct, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Rasilez Hct is flagged as the suspect drug causing the adverse event.

Most Common Rasilez Hct Adverse Events Reported to the FDA

What are the most common Rasilez Hct adverse events reported to the FDA?

Blood Pressure Increased
35 (1.83%)
Diarrhoea
34 (1.78%)
Hypertension
31 (1.62%)
Blood Creatinine Increased
28 (1.46%)
Malaise
28 (1.46%)
Nausea
28 (1.46%)
Dyspnoea
27 (1.41%)
Hyponatraemia
26 (1.36%)
Dizziness
23 (1.2%)
Atrial Fibrillation
22 (1.15%)
Renal Failure Acute
22 (1.15%)
Show More Show More
Vomiting
21 (1.1%)
Fatigue
20 (1.04%)
Syncope
20 (1.04%)
Hypokalaemia
17 (.89%)
Blood Pressure Inadequately Control...
15 (.78%)
Confusional State
15 (.78%)
Oedema Peripheral
15 (.78%)
Rash
15 (.78%)
Arrhythmia
14 (.73%)
Cardiac Failure
14 (.73%)
Diabetes Mellitus
14 (.73%)
Drug Interaction
14 (.73%)
Headache
14 (.73%)
Blood Pressure Fluctuation
13 (.68%)
Cerebrovascular Accident
13 (.68%)
Myocardial Infarction
13 (.68%)
Renal Failure
13 (.68%)
Asthenia
12 (.63%)
Drug Ineffective
12 (.63%)
Pruritus
12 (.63%)
Pyrexia
12 (.63%)
Urinary Tract Infection
12 (.63%)
Death
11 (.57%)
Fall
11 (.57%)
Gait Disturbance
11 (.57%)
Hypertensive Crisis
11 (.57%)
Blood Triglycerides Increased
10 (.52%)
Cytolytic Hepatitis
10 (.52%)
Gamma-glutamyltransferase Increased
10 (.52%)
Loss Of Consciousness
10 (.52%)
Angina Pectoris
9 (.47%)
Condition Aggravated
9 (.47%)
Dehydration
9 (.47%)
Flatulence
9 (.47%)
Hepatic Cirrhosis
9 (.47%)
Pneumonia
9 (.47%)
Transient Ischaemic Attack
9 (.47%)
Weight Decreased
9 (.47%)
Arthralgia
8 (.42%)
Blood Glucose Increased
8 (.42%)
Blood Pressure Decreased
8 (.42%)
Feeling Abnormal
8 (.42%)
General Physical Health Deteriorati...
8 (.42%)
Gout
8 (.42%)
Hyperuricaemia
8 (.42%)
Hypochloraemia
8 (.42%)
Infarction
8 (.42%)
Proteinuria
8 (.42%)
Tremor
8 (.42%)
Uterine Cancer
8 (.42%)
Anuria
7 (.37%)
Ascites
7 (.37%)
Blood Urea Increased
7 (.37%)
Cerebellar Infarction
7 (.37%)
Cerebral Ischaemia
7 (.37%)
Dysphagia
7 (.37%)
Hepatic Failure
7 (.37%)
Hyperkalaemia
7 (.37%)
Hypotension
7 (.37%)
Iron Deficiency Anaemia
7 (.37%)
Jaundice
7 (.37%)
Liver Injury
7 (.37%)
Pain In Extremity
7 (.37%)
Pancreatitis Acute
7 (.37%)
Renal Impairment
7 (.37%)
White Blood Cell Count Increased
7 (.37%)
Acute Myocardial Infarction
6 (.31%)
Affective Disorder
6 (.31%)
Alcoholic Liver Disease
6 (.31%)
Blood Pressure Diastolic Decreased
6 (.31%)
Bradycardia
6 (.31%)
Coronary Artery Disease
6 (.31%)
Erythema
6 (.31%)
Face Oedema
6 (.31%)
Haemoglobin Decreased
6 (.31%)
Hepatic Steatosis
6 (.31%)
Muscular Weakness
6 (.31%)
Oedema
6 (.31%)
Pain
6 (.31%)
Stress
6 (.31%)
Abdominal Pain Upper
5 (.26%)
Albuminuria
5 (.26%)
Angioedema
5 (.26%)
Anorectal Discomfort
5 (.26%)
Aortic Aneurysm
5 (.26%)
Blood Albumin Decreased
5 (.26%)
Blood Count Abnormal
5 (.26%)
Blood Urine
5 (.26%)
Brain Natriuretic Peptide Increased
5 (.26%)
Catheterisation Cardiac
5 (.26%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Rasilez Hct, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Rasilez Hct is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Rasilez Hct

What are the most common Rasilez Hct adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Rasilez Hct, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Rasilez Hct is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Rasilez Hct According to Those Reporting Adverse Events

Why are people taking Rasilez Hct, according to those reporting adverse events to the FDA?

Hypertension
285
Renal Disorder
4
Renin Increased
4
Essential Hypertension
3
Proteinuria
3
Blood Pressure Increased
2
Show More Show More
Renal Failure Chronic
2
Blood Pressure
2
Malignant Hypertension
1
Cardiac Failure
1
Hypertensive Crisis
1
Dyspnoea
1
Swelling
1

Rasilez Hct Case Reports

What Rasilez Hct safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Rasilez Hct. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Rasilez Hct.